Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.   Report issue

For profit Phase 1 Phase 3
Founded: Linyi China (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2017
NCT03125746
First Marketed Drug
2016
ipratropium (atrovent)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

LUOXIN AUROVITAS | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Esophagitis (Phase 3)

Gastroesophageal Reflux (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 10